1-(2-methoxyethyl)-1H-indole-6-carboxylic acid | 1304787-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(2-methoxyethyl)-1H-indole-6-carboxylic acid
• 英文别名: 1-(2-methoxyethyl)indole-6-carboxylic acid
• CAS: 1304787-78-7
• 化学式: C₁₂H₁₃NO₃
• mdl: MFCD18873302
• 分子量: 219.24
• InChiKey: NOTYXENUURHVNM-UHFFFAOYSA-N

物化性质

• 沸点：
  420.3±25.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE COMME BLOQUEURS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2011058766A1

  公开（公告）日：2011-05-19

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or -SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及式（I）的芳基羧酰胺衍生物，其中Ar1为苯基；Ar2为芳基；n为1-4；X为-O-、-S-、-SO-或-SO2-，其前体药物或其药学上可接受的盐，具有作为TTX-S通道的电压门控钠通道的阻塞活性，并且在治疗或预防涉及电压门控钠通道的疾病和疾病中如疼痛等方面具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病如疼痛中的用途。
• PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN
  申请人：Breitenstein Werner

  公开号：US20100087427A1

  公开（公告）日：2010-04-08

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.

  小说3-单一、3,4-二和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素不适当活性的疾病（=失调）；该类化合物用于制备用于治疗依赖于肾素不适当活性的疾病的制药配方；该类化合物用于治疗依赖于肾素不适当活性的疾病；包括所述取代吡咯烷化合物的制药配方和/或包括给予所述取代吡咯烷化合物的治疗方法，以及描述了制备所述取代吡咯烷化合物的新型中间体和部分步骤。所述取代吡咯烷化合物特别是公式I的取代基如说明书所述。
• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• US9051296B2
  申请人：——

  公开号：US9051296B2

  公开（公告）日：2015-06-09
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2006066896A2

  公开（公告）日：2006-06-29

  [EN] Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel inter­mediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula (I), wherein the substituents are as described in the specificacion.
  [FR] La présente invention concerne de nouveaux composés de pyrrolidine 3-mono-substitués, 3,4-di-substitués et 3,4,4,-tri-substitués, destinés à être utilisés pour le diagnostic et le traitement thérapeutique d'un animal à sang chaud, en particulier pour le traitement d'une maladie (= trouble) qui dépend d'une activité inappropriée de la rénine, l'utilisation d'un composé de cette classe pour la préparation d'une composition pharmaceutique pour traiter une maladie dépendant d'une activité inappropriée de la rénine, l'utilisation d'un composé de cette classe pour traiter une maladie qui dépend d'une activité inappropriée de la rénine, des compositions pharmaceutiques contenant un composé de pyrrolidine substitué susmentionné, et / ou une méthode de traitement consistant à administrer un composé de pyrrolidine substitué susmentionné, une méthode de préparation desdits composés de pyrrolidine substitués, et de nouveaux intermédiaires ainsi que des étapes partielles pour leur synthèse. Ces composés de pyrrolidine substitués sont représentés en particulier par la formule (I), les substituants étant tels que décrits dans le descriptif.